Differential Gene Expression May Predict Response to Somatostatin Analogues (SSAs) in Gastrointestinal (GI) Neuroendocrine Tumors (NETs) Abstract #2868

Introduction: SSAs are commonly used to treat GI NETs as they have anti-secretory and antiproliferative effects. However, genetic markers predicting response to SSAs are lacking.
Aim(s): We performed a genome wide evaluation of gene expression changes associated with response to SSAs in GI NETs.
Materials and methods: RNA was extracted from FFPE conserved tissue of 27 patients with NETs who previously received SSA treatment. Samples were hybridized against the human Clariom S Assays (Affymetrix). Data analysis was performed using the Bioconductor / R-package pd.clariom.s.human. Genes with at least 1.5-fold regulation and a p-value <0.01 were considered significant. Pathway and functional analysis were performed using WebGestalt (2013 edition).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Prof. Dr. Dr. Andreas Teufel

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Julie Refardt
#2988 Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells
Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: MSc Ilva Klomp
#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1
Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Anand Iyer
#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PD Dr. Patricia Grabowski